本期精選3篇婦產(chǎn)科相關領域文章，對摘要進行了翻譯，與婦產(chǎn)科同仁共讀：
1.Olaparib plus Durvalumab, with or without Bevacizumab, as Treatment in PARP Inhibitor-Na?ve Platinum-Sensitive Relapsed Ovarian Cancer: A Phase II Multi-Cohort Study
奧拉帕利聯(lián)合度伐利尤單抗作為PARP抑制劑初治鉑敏感復發(fā)性卵巢癌患者的治療：一項II期多隊列研究
2.Association of Continuous Glucose Monitoring Metrics With Pregnancy Outcomes in Patients With Preexisting Diabetes.
動態(tài)血糖監(jiān)測指標與糖尿病患者妊娠結局的關聯(lián)
3.Atezolizumab plus bevacizumab and chemotherapy for metastatic, persistent, or recurrent cervical cancer （BEATcc）: a randomised, open-label, phase 3 trial.
貝伐珠單抗聯(lián)合化療，同時加用阿替利珠單抗治療轉移性、持續(xù)性或復發(fā)性宮頸癌的3期臨床試驗
